Lana Ghanem
Founder & Managing Director @ Hikma Ventures
London, United Kingdom
Lana Ghanem is a Series A investor at Hikma Ventures in London focused on Health Care and Medical Device. Lana is managing director at Hikma Ventures which she helped establish in 2015. Lana started her career at Hikma Pharmaceuticals PLC in 2012 as the Assistant to the CEO and Director of Corporate Strategy & Development where she worked on strategic projects across the company’s various functions including strategy, M&A, operations andfinance.Prior to joining Hikma, Lana worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries.Lana holds an MBA from Harvard Business School (HBS) and a Bachelors of Commerce degree from McGill University.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Lana Ghanem invests in
Stages Lana Ghanem invests in
Countries Lana Ghanem invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 8 (57%)
- Medical Device 4 (29%)
- Medical 3 (21%)
- Biotechnology 3 (21%)
- Artificial Intelligence 3 (21%)
Stage
- Series A 5 (36%)
- Series B 5 (36%)
- Series C 2 (14%)
- Seed 1 (7%)
Country
- United States 7 (50%)
- United Arab Emirates 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | |
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series C / Mar 19, 2025 | |
|
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $30M / Series B / Jul 26, 2023 | |
Altibbi
|
Altibbi is a digital health platform that offers tools and information to provide access to health advice 24/7 anywhere through its website and apps. | $44M / Series B / Mar 28, 2022 | |
Activ Surgical
|
Activ Surgical is a digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility. Its scalable and patent-protected surgical software platform technology is driven by computer vision, artificial intelligence, analytics, and machine learning to enhance a surgeon’s intra-operative decision making,and reduce unintended and preventable surgical complications.The company was founded in 2017 and is headquartered in Boston, Massachusetts. | $15M / Series B / Mar 22, 2022 | |
NuvoAir
|
NuvoAir Medical is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions. NuvoAir’s care model integrates advanced monitoring technology and analytics with evidence-based interventions, all delivered by a multidisciplinary team. This approach ensures that each patient'sjourney is highly personalized. Collaborating with health plans and risk-bearing entities through flexible, value-based payment arrangements, NuvoAir distinguishes itself as a specialty care provider, effectively reducing healthcare costs and enhancing overall outcomes. | $11M / Series A / Jan 19, 2022 | |
|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series B / Nov 02, 2021 | |
Lemonaid Health
|
Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays.It was founded in 2013 and is headquartered inSan Francisco, California. | $36.8M / Series B / Jul 31, 2020 | |
Pillo Health
|
Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health andwellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device. | $11M / Series A / May 29, 2019 | |
|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $4.8M / Series A / Mar 28, 2019 | |
| See all 14 investments → | |||
Co-Investors
About Hikma Ventures
HV will act as an instrument of strategic growth in broadening Hikma’s offerings; it will allow Hikma to tap into opportunities in the growing digital health space.HV will invest in companies where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinationalpharmaceutical company.We will invest in companies at all stages of development, including start-ups, spinouts, and consortia investments.Our initial investment size is up to $5 million per round. HV will look at global opportunities but with a focus on the US and the Middle East & Africa (MEA).We seek to actively partner with the management teams of portfolio companies to realize the potential of their products and technologies.
Hikma Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Lana Ghanem
Founder & Managing Director
|
|||
|
Ahmad Fayyad
Associate
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lana Ghanem invest in?
Lana Ghanem invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lana Ghanem?
Public channels for Lana Ghanem include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Lana Ghanem last invest?
The most recent investment recorded for Lana Ghanem closed in Sep 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
